Modern glucagon-like peptide 1 (GLP-1) analogues and the combined gastric inhibitory polypeptide (GIP)/GLP‐1 agonist tirzepatide play an important role in the combined treatment of obesity and type 2 diabetes mellitus. This evidence concerns the gene GCG and obesity disorder.